Critically appraise and discuss recent findings on the immunopathogenesis of psoriasis, atopic dermatitis, psoriatic arthritis, and hidradenitis supperativa.
Describe recent advances in biologic and small molecule drug development for the treatment of immune-mediated inflammatory disease, with an emphasis on psoriasis, psoriatic arthritis, and atopic dermatitis.
Develop strategies to predict, prevent, and treat potential adverse effects and complications encountered with biologic agents.
Analyze recent clinical trials on the safety and efficacy of biologic and small molecule drugs for the treatment of psoriasis, psoriatic arthritis, and atopic dermatitis.
Review data regarding the comorbidities associated with psoriasis, psoriatic arthritis, and atopic dermatitis.
Through case-based presentations and discussion, develop individualized treatment plans for patients with psoriasis or AD.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and the Dermatology Education Foundation. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education, LLC designates this live activity for a maximum of 4 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA CONTINUING EDUCATION
PAs may claim a maximum of 4 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by ACCME or a recognized state medical society.
NURSE PRACTITIONER CONTINUING EDUCATION
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
This activity is designated for 2.25 pharmacology credits.